Symptomtext
reporting DAPTACEL, ADACEL, PENTACEL , IPOL, and FLUZONE QUADRIVALENT PREFILLED SYRINGES at a low of 0C for 17 hours, with no reported adverse event; Initial information received on 04-Jan-2022 regarding an unsolicited valid non-serious case received from a consumer/non-hcp. This case involves an unknown age and unknown gender patient who reported daptacel, adacel, pentacel , ipol, and fluzone quadrivalent prefilled syringes at a low of 0c for 17 hours, with no reported adverse event while receiving vaccines IPV (VERO) [IPOL], DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE [PENTACEL], DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE [ADACEL] and DIPHTHERIA-15/TETANUS/5 AC PERTUSSIS VACCINE [DAPTACEL] and with the use of medical device FLUZONE QUADRIVALENT PRE-FILLED SYRINGE. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, the patient started using FLUZONE QUADRIVALENT PRE-FILLED SYRINGE Unknown dosage unknown (lot - U7093AA, 30-Jun-2022). On an unknown date, the patient received a dose of suspect DIPHTHERIA-15/TETANUS/5 AC PERTUSSIS VACCINE lot C5743AA in unknown administration site. On an unknown date, the patient received a dose of suspect DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE lot U7093AA via unknown route in unknown administration site. On an unknown date, the patient received a dose of suspect DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE lot UJ582AAA via unknown route in unknown administration site. On an unknown date, the patient received a dose of suspect IPV (VERO) lot T1E872M in unknown administration site. On an unknown date the patient developed an event of a non-serious reporting daptacel, adacel, pentacel , ipol, and fluzone quadrivalent prefilled syringes at a low of 0c for 17 hours, with no reported adverse event (product storage error) (unknown latency) after starting use of FLUZONE QUADRIVALENT PRE-FILLED SYRINGE. Action taken was not applicable. It was not reported if the patient received a corrective treatment for the event (reporting DAPTACEL, ADACEL, PENTACEL , IPOL, and FLUZONE QUADRIVALENT PREFILLED SYRINGES at a low of 0C for 17 hours, with no reported adverse event). At time of reporting, the outcome was Unknown for the event reporting daptacel, adacel, pentacel , ipol, and fluzone quadrivalent prefilled syringes at a low of 0c for 17 hours, with no reported adverse event. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.